It will be important to establish if inhibition of EZH2 may potentially drive selection of antecedent myeloid clones to establish MPN, MDS, or AML (see Figure 3, IDH inhibitors and EZH inhibition). This evidence concerns the gene EZH2 and myeloproliferative disorder.